Chronic Kidney Disease(CKD)
Conditions
Interventions
Atrovastatin (10mg/day) is added in patients with medical diet.
Ezetimibe (10mg/day) is added in patients with medical diet. in case of insufficient effect,treatment with non-Statin medicine such as
Sponsors
Departmrnt of CKD initiatives,Nagoya university graduate school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)CKD patient who amalgamates GFR30-90 mL/min/1.73m2 and hypercholesterolemia.If hypercholesterolemia amalgamate the diabetic,LDL cholesterol is over 120mg/dL .If hypercholesterolemia isn't amalgamate the diabetic,LDL cholesterol is abobe 140mg/dL . The LDL cholesterol is excluded from the object for 180mg/dL or more regardless of the presence of the diabetic amalgamation. 2)Statin will not be taken in the past six months. 3)From 20 to less than 75 years old
Exclusion criteria
Exclusion criteria: 1)Defective diabetic for control(abobe FBS160mg/dL,HbA1c8%) 2)Familial hypercholesteremia. 3)The past of event of cardiovascular disease. 4)High blood pressure that cannot be controlled(above 140mg/dL) 5)Patient who has previous history of hypersensitivity for Atolbastatin or Ezetimibe 6)Woman who has pregnant woman or possibility of pregnancy 7)Patient who judged that it is improper that physician in charge puts it in to examination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of change and change rate ofinulin clearance and para amino hippuric acid clearance. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Filtration fraction (FF)filtration rate 2.Renal Vascular Resistance(RVR) 3.Serum creatinine 4.serum cystatin C 5.eGFR (Estimated glomerular filtration rate of Japanese calculated using creatinine and cystatin C ). 6.Creatinine production rate. 7.Liver-Type Fatty Acid Binding Protein(L-FABP). 8.proteinuria(g/gCr) and albuminuria(mg/gCr) | — |
Countries
Japan
Outcome results
None listed